Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement
- PMID: 37841645
- PMCID: PMC10570452
- DOI: 10.3389/ti.2023.11729
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement
Abstract
Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD) and a lead indication for liver transplantation (LT) in the western world. In this article, we present a Consensus Statement on LT practice, developed by a dedicated Guidelines' Taskforce of the European Society of Organ Transplantation (ESOT). The overarching goal is to provide practical guidance on commonly debated topics, including indications and timing of LT, management of bile duct stenosis in patients on the transplant waiting list, technical aspects of transplantation, immunosuppressive strategies post-transplant, timing and extension of intestinal resection and futility criteria for re-transplantation.
Keywords: IBD; PSC; immunosuppression; liver transplantation; retransplantation.
Copyright © 2023 Carbone, Della Penna, Mazzarelli, De Martin, Villard, Bergquist, Line, Neuberger, Al-Shakhshir, Trivedi, Baumann, Cristoferi, Hov, Fischler, Hadzic, Debray, D’Antiga, Selzner, Belli and Nadalin.
Conflict of interest statement
MC has received grant support unrelated to this study from Genetics spa, PSC Pediatric Foundation, AMAF, EpaC and AIRCS. He also received speakers/consultancy/advisory fees for GlaxoSmithKline, Dr. Falk Pharma, Cymabay, Advanz Pharma, Albireo, Ipsen, Mayoly Spindler, Perspectum, Echosens, Kowa, and Mirun. PT receives institutional support from Birmingham NIHR BRC. Unrelated to this study PT has received grant support from the Wellcome Trust, Innovate UK, the Medical Research Foundation, GlaxoSmithKline (GSK), Guts UK, PSC Support, LifeArc, NIHR, Intercept Pharma, Dr. Falk Pharma, Gilead Sciences, and Bristol Myers Squibb. He has also received speaker fees from Intercept and Dr. Falk, and advisory board/consultancy fees from Intercept, Cymabay, Pliant Pharma, Dr. Falk, Albireo, Ipsen and GlaxoSmithKine. HNH consultancies for Arrowhead, Takeda, GLG, Albireo, Alnylam and Mirum. LC received speakers fee from Advanz and Echosens. LD’A received consultancy fees from: Albireo, Mirum, Alexion, Astra Zeneca, Selecta, Vivet, Spark, Genespire, and Tome, in fields unrelated to the current topic. DD received consultancy fees from: Mirum, Vertex, Orphalan, Univar, Alexion, in fields unrelated to this study. UB received consultancy fees or grant support from: Mirum, Albireo, Alexion, Nestle and Vivet in fields unrelated to this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis.Liver Int. 2013 Jan;33(1):53-61. doi: 10.1111/j.1478-3231.2011.02677.x. Epub 2011 Nov 22. Liver Int. 2013. PMID: 22103794
-
Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report.Transplant Proc. 2015 Nov;47(9):2775-7. doi: 10.1016/j.transproceed.2015.09.043. Transplant Proc. 2015. PMID: 26680092
-
Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.Transplantation. 2003 Jun 27;75(12):1983-8. doi: 10.1097/01.TP.0000058744.34965.38. Transplantation. 2003. PMID: 12829898
-
Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.Am J Gastroenterol. 2013 Sep;108(9):1417-25. doi: 10.1038/ajg.2013.163. Epub 2013 Jul 30. Am J Gastroenterol. 2013. PMID: 23896954 Review.
-
Inflammatory bowel disease in liver transplanted patients.World J Gastroenterol. 2017 May 14;23(18):3214-3227. doi: 10.3748/wjg.v23.i18.3214. World J Gastroenterol. 2017. PMID: 28566881 Free PMC article. Review.
Cited by
-
Quantitative Magnetic Resonance Cholangiopancreatography Scoring and Its Predictive Value for Outcomes in Adults with Primary Sclerosing Cholangitis.J Clin Med. 2024 Aug 3;13(15):4548. doi: 10.3390/jcm13154548. J Clin Med. 2024. PMID: 39124814 Free PMC article.
References
-
- European Association for the Study of the Liver. Electronic Address: easloffice@easloffice.eu; European Association for the Study of the LiverEuropean Association for the Study of the Liver. EASL Clinical Practice Guidelines on Sclerosing Cholangitis. J Hepatol (2022) 77(3):761–806. 10.1016/j.jhep.2022.05.011 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical